Table 2 Variant agreement between tumor and plasma samples in variants detected in clinically relevant genes
From: Liquid biopsy as an option for predictive testing and prognosis in patients with lung cancer
Study ID | Gene | Variant | Tumor cell content (%) | Input cfDNA (ng) | AF (%) | |
|---|---|---|---|---|---|---|
Tumor samples | cfDNA | |||||
Concordant variants | ||||||
 4 | KRAS | p.Gly12Cys | 50 | 37.3 | 52.85 | 3.06 |
 5 | KRAS | p.Gly12Valb | 80 | 27.0 | NA | 2.09 |
 9 | EGFR | p.Glu746_Ala750del | 25 | 11.9 | 45.35 | 5.11 |
 18 | KRAS | p.Gly12Cys | 30 | 50.0 | 26.93 | 1.02 |
 25 | EGFR | p.Leu747_Pro753delinsSer | 20 | 50.0 | 45.83 | 2.28 |
 29 | PIK3CA | p.Glu545Lys | 20 | 44.7 | 20.41 | 8.10 |
 35 | ALK;EML4 | Fusion | 10 | 20.0 | NA | NA |
 42 | KRAS | p.Gly12Cys | 70 | 47.0 | 46.65 | 5.92 |
 51 | KRAS | p.Gly13Asp | 30 | 33.4 | 15.38 | 0.13 |
 52 | KRAS | p.Gly13Asp | 30 | 27.2 | 31.96 | 3.22 |
 55 | EGFR | p.Leu747_Glu749del | 20 | 20.5 | 39.53 | 5.80 |
 67 | KRAS | p.Gly12Cys | 10 | 50.0 | 19.01 | 3.38 |
 70 | ALK;EML4 | Fusionc | 10 | 13.9 | NA | NA |
 72 | EGFR | p.Leu858Arg | NAa | 50.0 | 1.65 | 0.19 |
 75 | KRAS | p.Gly12Cys | < 10 | 43.9 | 11.05 | 0.52 |
Discordant variants | ||||||
 1 | EGFR | p.Glu746_Ala750delb | 60 | 19.8 | NA | – |
 7 | KRAS | p.Gly12Ala | 70 | 15.6 | 12.43 | – |
 21 | EGFR | p.Glu746_Ser752delinsVal | 20 | 22.7 | 27.71 | – |
 32 | ROS1 | Fusionc | 80 | 25.8 | NA | – |
 33 | EGFR | p.Glu746_Ala750del | 30 | 29.1 | 62.85 | – |
 43 | KRAS | p.Gly12Cys | 5 | 35.7 | 8.15 | – |
 60 | ALK;EML4 | Fusion | 25 | 22.5 | NA | – |
 73 | KRAS | p.Gly12Ala | 20 | 38.1 | 15.08 | – |